Norstella

Norstella is a leading provider of data and analytics, software and consulting to the life sciences, payor, financial services and other industries, serving ~3,000 customers globally. Norstella provides clients with critical tools and expertise to navigate complexities and enhance decision-making at each step of the drug development and commercialization life cycle, ultimately smoothing the pathway of lifesaving therapies from pipeline to patient.

In 2018, WCAS Fund XII invested in MMIT, a leading provider of pharma market access solutions and scaled the platform to what is Norstella today through meaningful organic growth and the acquisitions of Zitter Health Insights, RJ Health, The Dedham Group and Panalgo and the mergers with Evaluate and Citeline. WCAS Fund XII exited the investment as part of Norstella’s merger with Citeline in 2022. WCAS Fund XIV subsequently invested in and jointly governs the combined platform alongside other financial sponsors.

Current CEO: Michael Gallup

Headquarters: Yardley, PA

Investment Year: 2022

Fund: Fund WCAS XIV